Interpreting Charles River ( CRL ) International Revenue Trends
Review Charles River's (CRL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Charles River ( CRL ) Q2 EPS Jumps 11%
Charles River Laboratories International ( NYSE:CRL ) , a global provider of laboratory services and research models for drug development, announced its latest earnings results on August 6, 2025. The company reported GAAP revenue of $1,032.1 million, slightly up 0.6% year-over-year ( GAAP ) , and ...
Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing - Charles River ( NYSE:CRL )
Q2 adjusted EPS of $3.12 beat estimates of $2.50, rising 11.4% year over year. FY25 EPS outlook raised to $9.90-$10.30 vs. prior guidance of $9.30-$9.80 The next correction is closer than you think. Find out how Tom Gentile plans to trade it, live on Wednesday. Charles River Laboratories ...
CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View
Charles River shares jump 9.3% pre-market after Q2 earnings and revenues beat estimates. The company raises its 2025 outlook.
Charles River Laboratories ( CRL ) Q2 Earnings and Revenues Surpass Estimates
Charles River (CRL) delivered earnings and revenue surprises of +24.80% and +5.01%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Organon ( OGN ) Beats Q2 Earnings and Revenue Estimates
Organon (OGN) delivered earnings and revenue surprises of +6.38% and +2.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AMN Healthcare Services ( AMN ) to Report a Decline in Earnings: What to Look Out for
AMN Healthcare (AMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Healthcare Analytical Testing Services Market is expected to generate a revenue of USD 9.56 Billion by 2031, Globally, at 11.20% CAGR: Verified Market Research®
Lewes, Delaware, July 31, 2025 ( GLOBE NEWSWIRE ) -- The Global Healthcare Analytical Testing Services Market Size is projected to grow at a CAGR of 11.20% from 2024 to 2031, according to a new report published by Verified Market Research®.
Charles River Laboratories ( CRL ) Expected to Beat Earnings Estimates: Should You Buy?
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Q2 Earnings Preview: What's in Store for the Stock?
CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.
RPM International Posts Better-Than-Expected Earnings, Joins ICON, MaxLinear, Nasdaq And Other Big Stocks Moving Higher On Thursday - Arrive AI ( NASDAQ:ARAI ) , ASGN ( NYSE:ASGN )
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Thursday. Shares of RPM International Inc. RPM rose sharply on Thursday following better-than-expected quarterly EPS and sales.
Will Charles River ( CRL ) Beat Estimates Again in Its Next Earnings Report?
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is it Prudent to Retain Charles River Stock in Your Portfolio Now?
CRL sees momentum in drug discovery and safety services, but macro pressures and currency headwinds threaten growth.
This Microsoft Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Bloom Energy ( NYSE:BE ) , Charles River ( NYSE:CRL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Liminatus Pharma Charts Dual-Front Attack on Cancer with IBA101 - Liminatus Pharma ( NASDAQ:LIMN )
La Palma, CA June 24, 2025 -- ( PR.com ) -- Next-generation CD47 inhibitor advances toward human trials in U.S. and Korea, with the prospect of safer, more potent immunotherapy.
Shoals Technologies Group, Inc. Appoints Industry Veteran, Bobbie L. King, Jr., as Chief Legal Officer
PORTLAND, Tenn., June 16, 2025 ( GLOBE NEWSWIRE ) -- Shoals Technologies Group, Inc. ( "Shoals" ) , a leading provider of electrical balance of system solutions for the global energy transition market, announced today that it has further strengthened its executive team with the addition of ...
Shoals Technologies Group, Inc. Appoints Industry Veteran, Bobbie L. King, Jr., as Chief Legal Officer - Shoals Technologies Gr ( NASDAQ:SHLS ) , HASI ( NYSE:HASI )
PORTLAND, Tenn., June 16, 2025 ( GLOBE NEWSWIRE ) -- Shoals Technologies Group, Inc. ( "Shoals" ) , a leading provider of electrical balance of system solutions for the global energy transition market, announced today that it has further strengthened its executive team with the addition of ...
Genomics Market to Hit US$66.8 Billion by 2029 with 9.4% CAGR | MarketsandMarkets™.
Delray Beach, FL, June 11, 2025 ( GLOBE NEWSWIRE ) -- The global genomics market, valued at US$42.4 billion in 2023, stood at US$42.6 billion in 2024 and is projected to advance at a resilient CAGR of 9.4% from 2024 to 2029, culminating in a forecasted valuation of US$66.8 billion by the end of ...
Why Is Charles River ( CRL ) Down 0.1% Since Last Earnings Report?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Charles River Stock May Gain From Extended CHDI Research Deal on HD
CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.
This Waste Management Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Charles River ( NYSE:CRL ) , Macerich ( NYSE:MAC )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Wolfe Research analyst Andrew Rosivach upgraded the rating for Newmark Group, Inc.
Should You Continue to Hold Charles River Stock in Your Portfolio?
CRL stays on investors' radars due to the strength of partnerships and segmental prospects.
Understanding Charles River ( CRL ) Reliance on International Revenue
Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Activist Elliott reaches key agreement with Charles River. Here are three ways to create value
The firm has three possible paths toward value creation at the drug development company.
Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization - Charles River ( NYSE:CRL )
Adjusted EPS rose to $2.34, beating estimates and up from $2.27 YoY. Revenue hit $984.2 million, beating consensus of $941.97 million despite a 2.7% YoY decline. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds profits in ...
Rockwell Automation Posts Better-Than-Expected Earnings, Joins Oscar Health, Charles River Laboratories, Walt Disney, Voya Financial And Other Big Stocks Moving Higher On Wednesday - Angi ( NASDAQ:ANGI ) , BorgWarner ( NYSE:BWA )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of Rockwell Automation, Inc. ROK rose sharply during Wednesday's session after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS and GAAP EPS ...
CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up
Charles River delivers better-than-expected earnings and revenues in the first quarter of 2025.
Charles River Laboratories ( CRL ) Beats Q1 Earnings and Revenue Estimates
Charles River (CRL) delivered earnings and revenue surprises of 13.59% and 5.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs
Company to use facility to further development of RetinalGenix's therapies for neurodegenerative and retinal diseases Company to use facility to further development of RetinalGenix's therapies for neurodegenerative and retinal diseases ...
RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs - RetinalGenix Technologies ( OTC:RTGN )
APOLLO BEACH, Fla., May 05, 2025 ( GLOBE NEWSWIRE ) -- RetinalGenix Technologies, Inc. RTGN ( "RetinalGenix" or the "Company" ) , announced today a new laboratory lease agreement with life science incubator MBC BioLabs for a brand new facility located in San Carlos, California.
Progyny ( PGNY ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Progyny (PGNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Charles River Laboratories ( CRL ) to Report a Decline in Earnings: What to Look Out for
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Charles River is Placed Just Ahead of Q1 Earnings
CRL's first-quarter 2025 performance is expected to have been hurt by a challenging biopharmaceutical environment.
Strength Seen in Charles River ( CRL ) : Can Its 6.9% Jump Turn into More Strength?
Charles River (CRL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing - Absci ( NASDAQ:ABSI ) , Charles River ( NYSE:CRL )
The U.S. Food and Drug Administration ( FDA ) announced its plans to end the mandatory animal testing of new drugs, a move that sent AI-enabled biotech companies such as Recursion Pharmaceuticals Inc. RXRX and Ginkgo Bioworks Holdings Inc. DNA rallying last week.
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday? - Simulations Plus ( NASDAQ:SLP ) , Certara ( NASDAQ:CERT ) , Charles River ( NYSE:CRL )
FDA to begin accepting AI-based models, lab-grown organoids instead of traditional animal tests for monoclonal antibody evaluations. A pilot program launching this year to assess non-animal-based testing for select therapies, with broader policy changes expected to follow.
Will Charles River ( CRL ) Beat Estimates Again in Its Next Earnings Report?
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bausch + Lomb ( BLCO ) Moves 13.9% Higher: Will This Strength Last?
Bausch + Lomb (BLCO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update
Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices after successfully passing all required safety testing ...
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate
Charles River and Valo Health identify a potential therapeutic for lupus using their combined offering, Logica.
ERS Genomics and Jumpcode Genomics sign CRISPR/Cas9 license agreement
DUBLIN and SAN DIEGO, March 27, 2025 /PRNewswire/ -- ERS Genomics Limited ( 'ERS' ) , the CRISPR licensing company, and Jumpcode Genomics ( 'Jumpcode' ) , a life science tools company improving and reducing the cost of next-generation sequencing technology, today announced a non-exclusive ...
Charles River ( CRL ) Up 1.9% Since Last Earnings Report: Can It Continue?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
This FedEx Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - FactSet Research Systems ( NYSE:FDS ) , Charles River ( NYSE:CRL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Goldman Sachs analyst Matthew Sykes downgraded the rating for Charles River Laboratories ...
Oncology Small Molecule Drugs Market is Expected to Expand at 5.9% CAGR, Reaching USD 167,635 Million by 2035 | Fact.MR Report
Rockville, MD , March 20, 2025 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the global oncology small molecule drugs market is estimated to reach a valuation of USD 94,494 million in 2025 and is expected to grow at a CAGR of 5.9% during the ...
Deciphering Charles River ( CRL ) International Revenue Trends
Examine the evolution of Charles River's (CRL) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance - Charles River ( NYSE:CRL )
Charles River's Q4 revenue fell 1.1% to $1B, beating estimates, while adjusted EPS rose to $2.66, surpassing the $2.53 consensus. The company expects 2025 revenue to decline 4.5%-7% and adjusted EPS of $9.10-$9.60, below the consensus of $9.60.
CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall
Charles River's organic revenue growth in Manufacturing Solutions is more than offset by lower revenues in the RMS and DSA segments.
Charles River Laboratories ( CRL ) Tops Q4 Earnings and Revenue Estimates
Charles River (CRL) delivered earnings and revenue surprises of 6.40% and 2.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Gear Up for Charles River ( CRL ) Q4 Earnings: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Is Now the Right Time to Hold on to Charles River Stock?
CRL's solid prospects in the DSA segment and strategic partnerships present a promising opportunity for investors.
